KR20150126671A - 소아 고형 종양의 치료 방법 - Google Patents

소아 고형 종양의 치료 방법 Download PDF

Info

Publication number
KR20150126671A
KR20150126671A KR1020157027992A KR20157027992A KR20150126671A KR 20150126671 A KR20150126671 A KR 20150126671A KR 1020157027992 A KR1020157027992 A KR 1020157027992A KR 20157027992 A KR20157027992 A KR 20157027992A KR 20150126671 A KR20150126671 A KR 20150126671A
Authority
KR
South Korea
Prior art keywords
subject
taxane
composition
years
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157027992A
Other languages
English (en)
Korean (ko)
Inventor
보우크라 베네타이브
일리애나 엘리아스
마커스 렌슐러
네일 피. 데사이
Original Assignee
아브락시스 바이오사이언스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아브락시스 바이오사이언스, 엘엘씨 filed Critical 아브락시스 바이오사이언스, 엘엘씨
Publication of KR20150126671A publication Critical patent/KR20150126671A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
KR1020157027992A 2013-03-13 2014-03-10 소아 고형 종양의 치료 방법 Ceased KR20150126671A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361780658P 2013-03-13 2013-03-13
US61/780,658 2013-03-13
US201361805817P 2013-03-27 2013-03-27
US61/805,817 2013-03-27
US201361829940P 2013-05-31 2013-05-31
US61/829,940 2013-05-31
US201361909868P 2013-11-27 2013-11-27
US61/909,868 2013-11-27
PCT/US2014/022541 WO2014143613A1 (en) 2013-03-13 2014-03-10 Methods of treatment of pediatric solid tumor

Publications (1)

Publication Number Publication Date
KR20150126671A true KR20150126671A (ko) 2015-11-12

Family

ID=51537501

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157027992A Ceased KR20150126671A (ko) 2013-03-13 2014-03-10 소아 고형 종양의 치료 방법

Country Status (12)

Country Link
US (1) US20160015817A1 (enExample)
EP (1) EP2968253A4 (enExample)
JP (3) JP6387389B2 (enExample)
KR (1) KR20150126671A (enExample)
CN (1) CN105209035A (enExample)
AU (2) AU2014228386B2 (enExample)
CA (1) CA2903470A1 (enExample)
HK (1) HK1219231A1 (enExample)
IL (1) IL240987A0 (enExample)
MX (1) MX2015011783A (enExample)
NZ (1) NZ630367A (enExample)
WO (1) WO2014143613A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US9675578B2 (en) 2006-12-14 2017-06-13 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
HRP20192259T1 (hr) 2009-04-15 2020-03-06 Abraxis Bioscience, Llc Pripravci nanočestica bez priona i metode njihove proizvodnje
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
AU2012249371B2 (en) 2011-04-28 2017-06-08 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
PL2790675T3 (pl) 2011-12-14 2019-12-31 Abraxis Bioscience, Llc Zastosowanie polimerowych rozczynników do liofilizacji lub zamrażania cząstek
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
JP6349381B2 (ja) 2013-03-12 2018-06-27 アブラクシス バイオサイエンス， エルエルシー 肺がんを処置する方法
JP6309610B2 (ja) 2013-03-14 2018-04-11 アブラクシス バイオサイエンス， エルエルシー 膀胱がんを処置する方法
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
SMT202100642T1 (it) 2015-06-29 2022-03-21 Abraxis Bioscience Llc Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi
AU2019239953B2 (en) 2018-03-20 2025-01-02 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
IL292439B2 (en) 2019-10-28 2026-05-01 Abraxis Bioscience Llc Pharmaceutical preparations of albumin and rapamycin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
CN1101700C (zh) * 1997-12-05 2003-02-19 上海众联生化技术开发有限公司 多肽口服液
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
CN1261161C (zh) * 2003-11-10 2006-06-28 钱汶光 复方干扰素诱生剂口含片
CN103169729A (zh) 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
CN101291658B (zh) 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
WO2008137148A2 (en) 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
EP2502078A1 (en) * 2009-11-20 2012-09-26 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
KR20130028727A (ko) * 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
CN103221042B (zh) * 2010-06-02 2016-02-10 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法

Also Published As

Publication number Publication date
MX2015011783A (es) 2015-12-01
JP2019163334A (ja) 2019-09-26
AU2019201357A1 (en) 2019-03-21
EP2968253A1 (en) 2016-01-20
JP2016512513A (ja) 2016-04-28
IL240987A0 (en) 2015-11-30
EP2968253A4 (en) 2016-11-02
CA2903470A1 (en) 2014-09-18
NZ630367A (en) 2017-02-24
US20160015817A1 (en) 2016-01-21
HK1219231A1 (zh) 2017-03-31
AU2014228386A1 (en) 2015-09-24
JP2018062528A (ja) 2018-04-19
AU2014228386B2 (en) 2018-11-29
CN105209035A (zh) 2015-12-30
JP6387389B2 (ja) 2018-09-05
WO2014143613A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
AU2014228386B2 (en) Methods of treatment of pediatric solid tumor
AU2018200347B2 (en) Methods of treatment of pancreatic cancer
TWI495467B (zh) 肝細胞癌之治療方法
JP6685875B2 (ja) 治療薬の組み合わせおよび投与の様式ならびに併用療法
KR20130080470A (ko) 증식성 질환의 치료를 위한 조합 치료 방법
KR20150065957A (ko) 암에 대항하는 베바시주맙과 조합된 파클리탁셀 및 알부민의 나노입자
KR20130109025A (ko) 방광암의 치료 방법
KR20190066033A (ko) 담도암의 치료 방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000